GENFIT

Share Issue/Capital Change • Jul 17, 2013

GENFIT: CONVERSIONS INTO SHARES OF 20 BONDS OCA2012-2

Lille (France), Boston (Massachusetts, United States), July 17th , 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the conversions into shares of 20 bonds OCA2012-2 in keeping with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd.

In keeping with the 1st and 2nd resolutions of the Extraordinary Shareholders' Meeting held on December 18th, 2012 and with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd ("the Bondholder"), the Bondholder requested one first conversion on July 15th , 2013 and then another conversion on July 16th , 2013 for a total value of €200,000.

The first conversion on July 15th , 2013 of 10 bonds OCA2012-2 into 24,379 new shares was performed at a conversion rate of €4.10, issue premium included, equivalent to 95% of the arithmetic mean of the volumeweighted average GENFIT share price for the five trading days (July 8th , 2013- July 12th , 2013) prior to the conversion request.

The other conversion on July 16th , 2013 of a total of 10 bonds OCA2012-2 into 23,759 new shares was performed at a conversion rate of €4.21, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five trading days (July 9th , 2013- July 15th , 2013) prior to the conversion requests.

As a result of these reserved share issues:

• The social capital of GENFIT has increased from €5,107,151 to €5,119,185.50;
• The number of shares representing the social capital of GENFIT has increased by 48,138, from 20,428.604 to 20,476,742 shares;
• The amount of the 7 th installment of the bond loan agreement that remains to be converted is €300,000.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board Ph. +333 2016 4000

MILESTONES – Press Relations Bruno Arabian Ph. +33 1 7544 8740 / +336 8788 4726 – barabian@milestones.fr